Our clinical case showed that patients with a Th2 phenotype who had an excellent response to this type of anti-IL-5R agent such as benralizumab could face hypersensitive reactions that demand stopping the medication, in this instance, a skin rash that resolved with standard therapy. This evidence concerns the gene IL5RA and Skin rash.